Researchers have developed a blood test that can reliably detect neuroendocrine prostate cancer and differentiate it from castration-resistant prostate cancer-adenocarcinoma (CRPC-adeno). Like a ...
Several novel therapies for castration-resistant prostate cancer (CRPC) have been approved with randomized phase III studies with continuing observational research either planned or ongoing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results